| pubmed-article:16809739 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C1167395 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C0205147 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C0021735 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C0332448 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C0456599 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C0004083 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C0018017 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C1817908 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C1718423 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C1709059 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C0600558 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:16809739 | lifeskim:mentions | umls-concept:C1571702 | lld:lifeskim |
| pubmed-article:16809739 | pubmed:issue | 19 | lld:pubmed |
| pubmed-article:16809739 | pubmed:dateCreated | 2006-6-30 | lld:pubmed |
| pubmed-article:16809739 | pubmed:abstractText | Adjuvant high-dose interferon-alfa-2b (HDI) improves disease-free and overall survival in patients with high-risk melanoma. However, its mechanism of action is largely unknown. Therefore, HDI was investigated in the neoadjuvant setting to assess clinical and pathologic responses after 4 weeks of HDI and to perform immunohistochemical evaluation of immune cell subsets and melanoma-associated antigens. | lld:pubmed |
| pubmed-article:16809739 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16809739 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16809739 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16809739 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16809739 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16809739 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16809739 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16809739 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16809739 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16809739 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16809739 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:16809739 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:16809739 | pubmed:author | pubmed-author:KirkwoodJohn... | lld:pubmed |
| pubmed-article:16809739 | pubmed:author | pubmed-author:Shipe-Spotloe... | lld:pubmed |
| pubmed-article:16809739 | pubmed:author | pubmed-author:MoschosStergi... | lld:pubmed |
| pubmed-article:16809739 | pubmed:author | pubmed-author:EdingtonHowar... | lld:pubmed |
| pubmed-article:16809739 | pubmed:author | pubmed-author:LandStephanie... | lld:pubmed |
| pubmed-article:16809739 | pubmed:author | pubmed-author:JukicDrazenD | lld:pubmed |
| pubmed-article:16809739 | pubmed:author | pubmed-author:RaoUma NUN | lld:pubmed |
| pubmed-article:16809739 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:16809739 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:16809739 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:16809739 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16809739 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16809739 | pubmed:pagination | 3164-71 | lld:pubmed |
| pubmed-article:16809739 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:meshHeading | pubmed-meshheading:16809739... | lld:pubmed |
| pubmed-article:16809739 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16809739 | pubmed:articleTitle | Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. | lld:pubmed |
| pubmed-article:16809739 | pubmed:affiliation | Melanoma and Skin Cancer Program, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. | lld:pubmed |
| pubmed-article:16809739 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16809739 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:16809739 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16809739 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16809739 | lld:pubmed |
